PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2497248

Practice management for ovulation induction.

L M Bonaventura
View original source ↗Export metadata ↓

Abstract

The use of Pergonal at a fixed dosage was evaluated in 200 women. The primary monitoring mode was vaginal ultrasonography. The overall pregnancy rate was 59% (118/200). The rates of multiple birth, hyperstimulation, spontaneous abortion and ectopic pregnancy were evaluated, also. The use of this regimen in private practice appears to be safe and effective.

Explore related subjects

Chorionic GonadotropinFemaleHumansMenotropinsOvarian FollicleOvulation DetectionOvulation InductionPregnancyPregnancy, MultipleUltrasonographyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L M Bonaventura. 1989. Practice management for ovulation induction.. https://pubmed.ncbi.nlm.nih.gov/2497248/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Elevated second trimester maternal serum beta-HCG concentrations and subsequent adverse pregnancy outcome.

Previous studies have found an association between elevated second trimester maternal serum alpha-fetoprotein (MS-AFP), in the absence of fetal anomalies, and adverse pregnancy outcome. We studied the association between elevated second trimester maternal serum beta-HCG, now also routinely measured by prenatal screening programs, and adverse pregnancy outcome by reviewing retrospectively the pregnancy outcomes among women with markedly elevated midtrimester beta-HCG in our prenatal screening program. Seven (0.23%) of 3,000 consecutively screened women had a serum beta-HCG above 5 MOM. Four (57%) of these 7 women had an adverse pregnancy outcome including severe preeclampsia (n = 2), abruptio placentae (n = 1), or preterm labor (n = 1). A concurrently elevated MS-AFP was found in only one of these 4 patients. Elevated mid-trimester maternal serum beta-HCG may be an independent risk factor for subsequent adverse pregnancy outcomes.

Chorionic Gonadotropin↗